Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Banwell, 2014, Multiple sclerosis in children, Handb Clin Neurol, 122, 427, 10.1016/B978-0-444-52001-2.00018-2 Boiko, 2002, Early onset multiple sclerosis: a longitudinal study, Neurology, 59, 1006, 10.1212/WNL.59.7.1006 Chitnis, 2013, Paediatric MS is the same disease as adult MS, Mult Scler, 19, 1255, 10.1177/1352458513488842 Ness, 2007, Clinical features of children and adolescents with multiple sclerosis, Neurology, 68, S37, 10.1212/01.wnl.0000259447.77476.a9 Waldman, 2016, Pediatric multiple sclerosis: clinical features and outcome, Neurology, 87, S74, 10.1212/WNL.0000000000003028 Gorman, 2009, Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis, Arch Neurol, 66, 54, 10.1001/archneurol.2008.505 Waubant, 2009, Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults, Arch Neurol, 66, 967, 10.1001/archneurol.2009.135 Renoux, 2007, Natural history of multiple sclerosis with childhood onset, N Engl J Med, 356, 2603, 10.1056/NEJMoa067597 Bar-Or, 2016, Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases, Neurology, 87, S12, 10.1212/WNL.0000000000002821 Chitnis, 2013, International pediatric MS study group clinical trials summit: meeting report, Neurology, 80, 1161, 10.1212/WNL.0b013e318288694e Ghezzi, 2015, Natalizumab in the pediatric MS population: results of the Italian registry, BMC Neurol, 15, 174, 10.1186/s12883-015-0433-y Krysko, 2020, Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis, Ann Neurol, 88, 42, 10.1002/ana.25737 Chitnis, 2018, Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis, N Engl J Med, 379, 1017, 10.1056/NEJMoa1800149 Confavreux, 2014, Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Neurol, 13, 247, 10.1016/S1474-4422(13)70308-9 Miller, 2014, Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Neurol, 13, 977, 10.1016/S1474-4422(14)70191-7 O'Connor, 2016, Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study, Neurology, 86, 920, 10.1212/WNL.0000000000002441 O'Connor, 2011, Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, 365, 1293, 10.1056/NEJMoa1014656 O'Connor, 2006, A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses, Neurology, 66, 894, 10.1212/01.wnl.0000203121.04509.31 Polman, 2005, Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”, Ann Neurol, 58, 840, 10.1002/ana.20703 Radue, 2017, Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA, Neurol Neuroimmunol Neuroinflamm, 4, e390, 10.1212/NXI.0000000000000390 Sprenger, 2019, Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide, Mult Scler, 26, 1207, 10.1177/1352458519855722 Vermersch, 2014, Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial, Mult Scler, 20, 705, 10.1177/1352458513507821 Krupp, 2013, International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions, Mult Scler, 19, 1261, 10.1177/1352458513484547 Verhey, 2013, Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials, Neurology, 81, 1215, 10.1212/WNL.0b013e3182a6cb9b Montalban, 2018, ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis, Mult Scler, 24, 96, 10.1177/1352458517751049 Rae-Grant, 2018, Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology, Neurology, 90, 777, 10.1212/WNL.0000000000005347 Wassmer, 2016, International pediatric MS study group global members symposium report, Neurology, 87, S110, 10.1212/WNL.0000000000002880 Wolinsky, 2013, Magnetic resonance imaging outcomes from a phase III trial of teriflunomide, Mult Scler, 19, 1310, 10.1177/1352458513475723 2019 Vukusic, 2020, Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience, Mult Scler, 26, 829, 10.1177/1352458519843055 Waubant, 2019, Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG, Neurology, 92, e2538, 10.1212/WNL.0000000000007572 Chitnis, 2012, Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis, Mult Scler, 18, 116, 10.1177/1352458511430704